ALK-Targeted Therapy Appears Beneficial in Patients with Adult-Onset Neuroblastoma

TOP - November 2021 Vol 14, No 7 - Neuroblastoma

ALK inhibitor therapy achieved “remarkable” response rates in a small study of patients with ALK-positive adult-onset neuroblastoma. Some patients who did not respond to initial treatment with 1 ALK inhibitor had a subsequent response to lorlatinib (Lorbrena), which had the best showing among ALK inhibitors evaluated in this setting. The results of this retrospective study were presented at the American Society of Clinical Oncology 2021 virtual annual meeting.

“Adult-onset neuroblastoma is a rare cancer that is challenging to treat, because patients cannot tolerate the chemotherapy regimens used on children. ALK is an appealing drug target and use of an ALK inhibitor can be a well-tolerated option for treatment of these patients, improving response and time to disease progression,” said lead investigator Jessica Stiefel, MD, Third Year Pediatric Hematology/Oncology Fellow, Memorial Sloan Kettering Cancer Center, New York City.

“Our experience shows that development of resistance to 1 ALK inhibitor does not preclude use of other agents within the same drug class. Overall, ALK-targeted therapy appears to be a safe and effective option for adult-onset neuroblastoma and should be considered when making this diagnosis,” she added.

Neuroblastoma typically occurs in children, with a median onset at age 5, and is usually treated with chemotherapy and radiation. Adult-onset neuroblastoma is a rare and biologically distinct cancer compared with childhood neuroblastoma.

“Adult-onset neuroblastoma is metastatic, chemotherapy-resistant, and almost invariably fatal,” Dr Stiefel explained. “The presence of ALK mutations in adult-onset neuroblastoma provides an opportunity for targeted therapy for a disease that is otherwise very challenging to treat.”

Study Details

Dr Stiefel presented data from a retrospective review based on 23 adult patients with adult-onset neuroblastoma who were genetically sequenced at Memorial Sloan Kettering Cancer Center between 2014 and 2020. Fourteen (61%) patients were found to harbor ALK somatic mutations. Of these 14, 7 were treated with 1 or more FDA-approved ALK inhibitors. Her presentation focused on these 7 patients.

One patient was diagnosed with the disease at age 12 years, and the other 6 at ages ranging from 28 to 68 years. Patients were treated with 1 to 4 previous regimens. Most had measurable disease at treatment initiation and had metastatic disease at diagnosis. Previous multimodality treatment included surgery, chemotherapy, and radiation.

Overall, treatment with ALK inhibitors was well-tolerated. Dizziness, drowsiness, and hallucinations were reported in 1 patient each, and these effects resolved when treatment was stopped. Grade 1 nausea and vomiting were reported in 6 patients. Treatment discontinuations were reported in 4 patients taking crizotinib (Xalkori) and alectinib (Alecensa).

“Lorlatinib was the best tolerated ALK inhibitor,” Dr Stiefel said. “No patient receiving lorlatinib required discontinuation due to adverse events, and 1 required a dose reduction.”

All 7 patients had an initial response to an ALK inhibitor, but 6 discontinued due to progressive disease or adverse events (3 each). Median time to progression was 15.5 months. Median overall survival was 46.5 months (range, 17-74 months).

Four patients treated with more than 1 ALK inhibitor continued to be in response and were started on lorlatinib therapy after disease progression on other ALK inhibitors. Two patients had stable disease.

Related Items
Dostarlimab Elicits 100% Complete Response Rate in Cohort of Patients with dMMR Rectal Cancer
Patricia Stewart
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in ASCO 2022 Highlights
Peptide-Based CoVac-1 Vaccine Shows Promise Against COVID-19 in Patients with Cancer
Patricia Stewart
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in COVID-19 & Cancer
Acalabrutinib Shows Promise in Patients with MZL
Patricia Stewart
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in ASCO 2022 Highlights
Collaboration Among Oncologists and Primary Care Providers Key to Closing the “Black Hole” in Survivorship Care
Patricia Stewart
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in Survivorship
Genetic Score Makes PSA Screening More Accurate
Patricia Stewart
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in Prostate Cancer
Updated Results from KEYNOTE-564 Confirm Benefit of Adjuvant Pembrolizumab for Patients with Renal-Cell Carcinoma at High Risk for Recurrence
Patricia Stewart
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in Renal-Cell Carcinoma
Sacituzumab plus Pembrolizumab Shows Encouraging Antitumor Activity in Metastatic Urothelial Cancer
Patricia Stewart
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GU 2022 Highlights
Circulating Tumor DNA Profiling May Result in Improved Detection and Treatment of CNS Lymphoma
Patricia Stewart
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASH 2021 Highlights
Pembrolizumab plus Chemotherapy Prolongs Survival in Patients with Triple-Negative Breast Cancer and PD-L1 Combined Positive Score ≥10
Patricia Stewart
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in SABCS
Study Finds 1 in 6 Patients with Cancer Experience “Long-Haul” COVID-19
Patricia Stewart
TOP - March 2022 Vol 15, No 2 published on February 28, 2022 in COVID-19 & Cancer
Last modified: November 12, 2021